Study identifier:D5130L00019
ClinicalTrials.gov identifier:NCT01611272
EudraCT identifier:N/A
CTIS identifier:N/A
A Post Marketing Surveillance to evaluate the safety and efficacy of Brilinta
Acute Coronary Syndromes
N/A
No
-
All
3402
Observational
19 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -
Verified 01 Jul 2017 by AstraZeneca
AstraZeneca
-
To identify the following items through the post marketing surveillance under routine clinical practice after marketing authorization of Brilinta Tablet: the occurrence of unrevealed Serious Adverse Events (SAEs), current status of occurrence of Adverse Events (AEs), the factors that may influence safety and efficacy of the drug.
A Post Marketing Surveillance to evaluate the safety and efficacy of Brilinta
Location
Location
Goyang-si, Gyeonggi-do, Republic of Korea
Location
Seoul, Seoul, Republic of Korea
Location
Cheonan-si, Chungcheongnam-do, Republic of Korea
Location
Ansan-Si, Gyeonggi-do, Republic of Korea
Location
Busan, Busan, Republic of Korea
Location
Andong-si, Gyeongsangbuk-do, Republic of Korea
Location
Incheon, Incheon, Republic of Korea
Location
Daegu, Daegu, Republic of Korea
Arms | Assigned Interventions |
---|---|
1 Unstable angina, Non ST-segment Elevation Myocardial Infarction or ST-segment elevation myocardial infarction including patients managed medically, and those who are managed with percutaneous coronary intervention or coronary artery by-pass grafting | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.